New hope for HER2 cancers: targeted drug shows promise in Mid-Stage trial

NCT ID NCT02675829

Ongoing Disease control Sponsor: Memorial Sloan Kettering Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial is testing a drug called ado-trastuzumab emtansine (Kadcyla) in 131 adults with advanced solid tumors that have a specific HER2 gene change. The drug combines an antibody that targets HER2 with a chemotherapy agent, aiming to deliver treatment directly to cancer cells. Researchers are measuring how many patients' tumors shrink or disappear. The study is active but no longer recruiting new participants.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ado-trastuzumab emtansine (a targeted drug that delivers chemotherapy directly to HER2-positive cancer cells)
What this could lead to: If successful, this could provide a new treatment option for people with certain HER2-driven cancers, especially lung and bladder cancers, that are hard to treat.
What could go wrong: This is a phase 2 trial with only 131 participants, so results may not apply to everyone. The drug can cause side effects like liver damage or heart problems, and it may not shrink tumors in all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BLADDER CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

benign urinary system neoplasm lung cancer lung carcinoma lung neoplasm malignant urinary system neoplasm urinary bladder carcinoma Urinary Bladder Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BLADDER CANCER LUNG CANCER SOLID TUMOR CANCERS URINARY TRACT CANCERS

Contacts and locations

Locations

Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities)

Basking Ridge, New Jersey, 07920, United States
Memorial Sloan Kettering Bergen (Limited Protocol Activities)

Montvale, New Jersey, 07645, United States
Memorial Sloan Kettering Cancer Center

New York, New York, 10065, United States
Memorial Sloan Kettering Cancer Center @ Suffolk - Commack (Limited Protocol Activities)

Commack, New York, 11725, United States
Memorial Sloan Kettering Monmouth (Limited Protocol Activities)

Middletown, New Jersey, 07748, United States
Memorial Sloan Kettering Nassau (Limited Protocol Activities)

Uniondale, New York, 11553, United States
Memorial Sloan Kettering Westchester (Limited Protocol Activities)

Harrison, New York, 10604, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.